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Abstract: Chicory (Cichorium intybus L.) is an important industrial crop cultivated mainly to extract
the dietary fiber inulin. However, chicory also contains bioactive compounds such as sesquiterpene
lactones and certain polyphenols, which are currently discarded as waste. Plants are an important
source of active pharmaceutical ingredients, including novel antimicrobials that are urgently needed
due to the global spread of drug-resistant bacteria and fungi. Here, we tested different extracts
of chicory for a range of bioactivities, including antimicrobial, antifungal and cytotoxicity assays.
Antibacterial and antifungal activities were generally more potent in ethyl acetate extracts compared
to water extracts, whereas supercritical fluid extracts showed the broadest range of bioactivities
in our assays. Remarkably, the chicory supercritical fluid extract and a purified fraction thereof
inhibited both methicillin-resistant Staphylococcus aureus (MRSA) and ampicillin-resistant Pseudomonas
aeruginosa IBRS P001. Chicory extracts also showed higher antibiofilm activity against the yeast
Candida albicans than standard sesquiterpene lactone compounds. The cytotoxicity of the extracts was
generally low. Our results may thus lead to the development of novel antibacterial and antifungal
preparations that are both effective and safe for human use.
Keywords: chicory; bioactivity; antimicrobial; antifungal; biofilm; cytotoxicity
1. Introduction
Chicory (Cichorium intybus L. var sativum) is a leafy biennial or perennial plant with
a strong fleshy taproot that can grow up to 75 cm in length. It belongs to the family
Asteraceae, which comprises ~23,000 species that grow in temperate climate zones around
the world. Chicory is an important source of the dietary fiber and industrial feedstock
inulin [1,2]. It is cultivated commercially for this purpose, especially in western Europe,
with an average inulin content of 17% by weight of fresh root biomass [3].
Similar to many asters, chicory also has a long history as a medicinal plant [4], which
can largely be attributed to the accumulation of sesquiterpene lactones (STLs) with a
broad range of health-promoting properties, including antimicrobial, anti-inflammatory
and anti-cancer activities [5–7]. The major STLs in chicory are derived from germacrene
A. The most abundant are lactucin, lactucopicrin, 8-deoxylactucin and their oxalate and
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glucoside derivatives [8,9]. Lactucin and lactucopicrin are responsible for the antimalarial
properties of chicory. Parthenolide, another germacranolide lactone with antiparasitic
activity, is produced by feverfew (Tanacetum parthenium (L.) Sch.Bip.) and has anti-cancer
and migraine prophylaxis properties [10]. Previous work confirmed the suitability of using
supercritical fluid extraction (SFE) to obtain STL from chicory roots [11].
The production of antimicrobial compounds by plants such as chicory offers a potential
solution to the growing threat of antibiotic-resistant pathogens. Although the global
antibiotics market is expected to reach a value of USD 62.06 billion by 2025, few compounds
with novel mechanisms of action are in the development pipeline [12]. Antibiotics are used
indiscriminately in vast quantities in medicine and agriculture, resulting in the emergence
of pathogen strains resistant to all known antibiotics used in the clinic, and the increasing
prevalence of multidrug-resistant strains of Staphylococcus aureus, Pseudomonas aeruginosa,
and Enterococcus faecium [13]. The cost of treatment for infections caused by antibiotic-
resistant bacteria increases by up to USD 40,000 per patient compared to susceptible
strains [14]. The health burden of infections caused by antibiotic-resistant bacteria in the
European Union is comparable to that of influenza, tuberculosis and HIV/AIDS combined,
with annual costs of EUR 1.1 billion [15]. There is also a growing threat of untreatable
infections. For example, vancomycin is often used as an antibiotic of last resort and is
recommended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections, but
vancomycin-resistant strains have emerged over the last 20 years [16]. Novel antimicrobial
compounds from plants could also help to address the drawbacks of current antifungal
drugs. For example, the broad-spectrum drug amphotericin B has potent antifungal activity
but causes significant nephrotoxicity-related side effects, and other synthetic antifungal
agents affect the endocrine, nervous, reproductive and immune systems [17,18].
Plants synthesize many compounds with antimicrobial activity but only a small
number ultimately complete clinical development and reach the market [19]. One reason
for this is that pure ingredients tend to be less potent than extracts containing mixtures
of antimicrobial compounds. Accordingly, the detection of antimicrobial activity in plant
extracts does not always indicate the presence of a highly potent single ingredient but is
more likely to reflect the synergistic activity of multiple ingredients acting on different
metabolic and physiological targets in the pathogen [20]. Given that it is easier for microbes
to evolve resistance to a single compound than multiple compounds with diverse targets,
the development of antimicrobial extracts may offer a solution to the challenge of multidrug-
resistant pathogens, and the use of well-characterized crop species increases the likelihood
that such extracts will be safe for human use. Accordingly, we compared the bioactivities of
different chicory extracts and pure compounds to determine the potential of this plant as a
source of antimicrobial ingredients. The exploitation of chicory in this manner would also
be economically advantageous by allowing the utilization of an industrial waste stream.
2. Results
2.1. Composition of the Extracts
Industrial chicory and witloof (Belgian endive) extracts containing STLs were ob-
tained by solvent extraction and SFE. The major STLs identified in each extract are
shown in Table 1. All extracts contained mixtures of 11β,13-dihydrolactucin, lactucin,
8-deoxylactucin, 11β,13-dihydro-8-deoxylactucin, 11β,13-dihydrolactucopicrin and lac-
tucopicrin at different ratios (Supplementary Figure S1). The supercritical fluid extract
fraction purified by flash column chromatography (Ci_SFEpur) contained a mixture of
8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin. Antimicrobial activity was tested
using a diverse panel of assays, focusing on typical human pathogens that are abundant on
the skin and in the gut to evaluate the potential of the compounds and extracts for topical
and oral application.
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Table 1. Industrial chicory and witloof extracts used in the bioactivity assays.
STL (µg/mg Extract) *









2.13 2.08 1.07 2.23
Wit_EtOAc Freeze-driedwitloof
Ethyl acetate extract
(S-L extraction) 0.86 1.35 1.18 3.17
Ci_H2O Fresh chicory
Water extract (S-L
extraction) 0.48 1.13 0.39 1.76
Ci_EtOAc Fresh chicory Ethyl acetate extract(S-L extraction) 4.81 8.09 3.18 26.88
Ci_SFE Freeze-driedchicory
Supercritical fluid
extraction (SFE) 36.31 109.31 19.50 262.19
Ci_SFEopt
Freeze-dried







- - - -
* Approximate quantification by using external calibration curves of commercially available standards (n ≥ 2). ** Composed only of a
mixture of 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin.
2.2. Antibacterial Activity
Chicory extracts and pure compounds generally showed higher activity against
Gram-positive Staphylococcus aureus VTT E-70045 than Gram-negative Escherichia coli
VTT E-94564T or Pseudomonas aeruginosa VTT E-96728 (Table 2). The Ci_SFE extract
showed strong antibacterial activity, whereas the witloof and chicory ethyl acetate ex-
tracts (Wit_EtOAc and Ci_EtOAc) showed moderate activity, and the witloof water extract
(Wit_H2O) showed only weak activity. The pure compounds lactucopicrin, parthenolide
and 11β-13-dihydrolactucopicrin moderately inhibited the growth of S. aureus, whereas
lactucin was a weak inhibitor (Table 2). All the standard compounds showed weak antimi-
crobial activity against E. coli and P. aeruginosa.
Witloof was used to assess the most suitable extraction solvent for optimized bioactiv-
ity. The strongest antimicrobial activity against S. aureus VTT E-70045 was achieved using
ethyl acetate (Wit_EtOAc) and SFE (Ci_SFE), resulting in moderate and strong growth
inhibition, respectively, at concentrations of 1 mg/mL (Supplementary Figure S2). The
final bacterial colony forming unit (CFU) counts in the S. aureus cultures after incuba-
tion for 48 h differed from control cultures by 1 (Wit_EtOAc) and 1.5 (Ci_SFE) log units,
indicating > 90% growth inhibition. Two chicory extracts were prepared from fresh in-
dustrial chicory root using ethyl acetate (Ci_EtOAc) or water (Ci_H2O) as solvents. As
observed for the pure compounds, Ci_EtOAc showed weak activity against E. coli and
P. aeruginosa (growth inhibition < 5%) at a concentration 0.05 mg/mL in dimethylsulfox-
ide (DMSO) but a stronger effect against S. aureus (growth inhibition = 20%). Ci_H2O
showed weak activity against S. aureus. The water extracts contained lactucin, 11β,13-
dihydrolactucin, 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin, whereas the ethyl
acetate extracts mainly contained 11β,13-dihydrolactucin, 8-deoxylactucin, 11β,13-dihydro-
8-deoxylactucin and 11β,13-dihydrolactucopicrin (Supplementary Figure S1). Neither of
the extracts showed antimicrobial activity against S. aureus MRSA. The results with witloof
and industrial chicory extracts indicated that higher antimicrobial activity can be achieved
by extraction with ethyl acetate than water, but that SFE was the most promising method.
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(0.05 mg/mL) ++ + +
Ci_H2O
(1.00 mg/mL) * + - NA
Wit_EtOAc
(1.00 mg/mL) ++ - NA
Wit_H2O
(1.00 mg/mL) - - NA
Ci_SFE
(1.00 mg/mL) +++ - NA
- no activity, + weak, ++ moderate (0.5 log reduction CFU/mL after 48 h), +++ strong (1.0 log reduction CFU/mL
after 48 h); NA, not applicable; * dissolved in ethanol.
The same extracts and standard compounds were tested using the microdilution
method. In agreement with our earlier results, Ci_EtOAc showed antimicrobial activity
against all the test pathogens except the resistant P. aeruginosa strain IBRS P001, whereas
Ci_H2O showed no antimicrobial activity at the concentrations we tested (Table 3). The stan-
dards (parthenolide and lactucopicrin) showed slightly better antimicrobial activity than
Ci_EtOAc, with minimal inhibitory concentrations (MICs) in the range 0.08–0.50 mg/mL.
Only costunolide and 11β-13-dihydrolactucin were active against P. aeruginosa IBRS P001
(MIC = 0.5 mg/mL) and none of the standards inhibited E. coli (Table 3). However, weak
activity was observed in the original assay (Table 1), probably reflecting the use of different
bacterial strains (E. coli ATCC 25922 and VTT E-94564T, respectively). Lactucin showed no
activity against any of the tested bacteria. Commercial antibiotics were used as controls
and showed better activity than the extracts and standards.
Ci_SFEopt and particularly Ci_SFEpur showed potent antimicrobial activity against
S. aureus and S. aureus MRSA (Figure 1). Ci_SFEpur showed a stronger inhibitory effect over
time, whereas Ci_SFEopt was most active during the first 24 h followed by the moderate
recovery of bacterial growth. These extracts had no effect against P. aeruginosa (data not
shown). Microdilution assays revealed promising antibacterial properties for Ci_SFEpur
and Ci_SFEopt, with MICs of 0.06–0.25 and 0.5–2.1 mg/mL, respectively (Table 4). Ci_SFEpur
appeared more potent than Ci_SFEopt. The most sensitive bacterial species was P. aeruginosa
IBRS P001 (MIC Ci_SFEpur = 0.06 mg/mL; MIC Ci_SFEopt = 0.50 mg/mL). The activity
of the extracts against the antibiotic-resistant S. aureus MRSA and P. aeruginosa IBRS P001
strains is particularly noteworthy given the urgent need for new drugs against antibiotic-
resistant pathogens.
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Table 3. Antibacterial activity of Ci_EtOAc and Ci_H2O and pure standard compounds (mg/mL). MIC, minimal inhibitory
concentration; MBC, minimal bactericidal concentration.







Extracts MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
Ci_EtOAc 0.75 1.50 0.75 1.50 1.50 3.00 - - 6.00 6.00
Ci_H2O - - - - - - - - - -
Standards
Costunolide - - - - - - 0.50 1.00 - -
Parthenolide 0.08 0.16 0.16 0.31 0.31 0.63 - - - -
Lactucin - - - - - - - - - -
Lactucopicrin - - 0.16 0.31 0.31 0.63 0.50 1.00 - -
11β, 13-Dihydrolactucin - - - - - - 0.50 1.00 - -
Controls
Ampicillin 0.002 0.003 0.002 0.003 0.0002 0.0004 - - 0.003 0.003
Streptomycin 0.006 0.012 0.050 0.100 0.0004 0.0008 0.050 0.100 0.030 0.030
- No antimicrobial activity with the tested concentrations.




Figure 1. Growth inhibition by Ci_SFEopt and Ci_SFEpur at a concentration of 5 mg/mL against (A) S. aureus, and (B) S. 
aureus MRSA. Green, Ci_SFEpur; orange, Ci_SFEopt, black, microbial control. 
Table 4. Antibacterial activities of Ci_SFEpur and Ci_SFEopt (mg/mL). MIC, minimal inhibitory concentration; MBC, mini-
mal bactericidal concentration. 
Strain 
Ci_SFEpur Ci_SFEopt  Ampicillin 
MIC MBC MIC MBC MIC MBC 
Proteus mirabilis 
ATCC 7002 0.25 0.50 2.10 4.40 0.01 0.01 
Listeria monocytogenes NCTC 7973 0.25 0.50 1.05 2.1 0.40 0.50 
Pseudomonas aeruginosa IBRS P001 0.06 0.12 0.50 1.00 - - 
Enterobacter cloacae human isolate 0.25 0.50 2.10 4.40 0.10 0.15 
Yersinia enterocolitica 
ATCC 23715 
0.25 0.50 2.10 4.40 0.004 0.008 
Klebsiella pneumoniae 
ATCC 13883 
- - 0.50 1.00 0.20 0.40 
Campylobacter jejuni 
ATCC 33560 
0.25 0.50 1.00 2.10 0.02 0.04 
- No antimicrobial activity at the tested concentrations. 
Next, we used thin layer chromatography (TLC) bioautography to screen our extracts 
and compounds for their biological activity. Ci_SFEopt was active against all tested micro-
organisms with Rf values ranging from 0.18 to 0.88 (Figure 2A,B). The purified SFE frac-
tion (Ci_SFEpur, Rf = 0.76) was active against the S. aureus oral isolate, S. aureus ATCC, P. 
aeruginosa and also the fungus Candida krusei. 
A 
B 
Figure 1. Growth inhibition by Ci_SFEopt and Ci_SFEpur at a concentration of 5 mg/mL against
(A) . aureus, d (B) S. aureus MRSA. G een, Ci_SFEpur; orange, Ci_SFEopt, black, microbial control.
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MIC MBC MIC MBC MIC MBC
Proteus mirabilis
ATCC 7002 0.25 0.50 2.10 4.40 0.01 0.01
Listeria monocytogenes
NCTC 7973 0.25 0.50 1.05 2.1 0.40 0.50
Pseudomonas aeruginosa
IBRS P001 0.06 0.12 0.50 1.00 - -
Enterobacter cloacae
human isolate 0.25 0.50 2.10 4.40 0.10 0.15
Yersinia enterocolitica
ATCC 23715 0.25 0.50 2.10 4.40 0.004 0.008
Klebsiella pneumoniae
ATCC 13883 - - 0.50 1.00 0.20 0.40
Campylobacter jejuni
ATCC 33560 0.25 0.50 1.00 2.10 0.02 0.04
- No antimicrobial activity at the tested concentrations.
Next, we used thin layer chromatography (TLC) bioautography to screen our extracts
and compounds for their biological activity. Ci_SFEopt was active against all tested mi-
croorganisms with Rf values ranging from 0.18 to 0.88 (Figure 2A,B). The purified SFE
fraction (Ci_SFEpur, Rf = 0.76) was active against the S. aureus oral isolate, S. aureus ATCC,
P. aeruginosa and also the fungus Candida krusei.
2.3. Antifungal Activity
The development of antifungal drugs is challenging because both the pathogen and
host are eukaryotic, limiting the number of suitable molecular targets. Drug-resistant fungal
strains have also been reported, including Candida species resistant to the common antifungal
fluconazole [21]. We found that all our compounds and extracts inhibited the growth of the
four Candida species we tested, as well as two strains of C. albicans (MIC = 0.03–1.00 mg/mL)
(Table 5). The most potent extracts were Ci_SFEopt and Ci_SFEpur, which inhibited all five
fungi in the test panel and achieved a MIC of 0.03 mg/mL against C. auris, which was
lower than the MIC of any of the pure compounds. None of the tested standards showed
activity against micromycetes (Table 5). Ci_EtOAc showed antifungal activity against
Aspergillus versicolor, A. ochraceus, A. niger, Trichoderma viride and Penicillium ochrochloron,
whereas Ci_H2O was moderately active solely against C. albicans (Table 5). Ci_SFEopt,
and Ci_SFEpur showed particularly potent activity against A. fumigatus, A. versicolor and
A. ochraceus, with Ci_SFEpur achieving MICs lower than the commercial antifungal agent
ketoconazole (Table 5).
2.4. Antibiofilm Activity
Chicory extracts demonstrated higher antibiofilm activity against C. albicans than
standard sesquiterpene lactone compounds. However, Ci_EtOAc and Ci_H2O achieved
higher antibiofilm activities than Ci_SFEopt and Ci_SFEpur (Table 5), despite the more
potent antifungal activities of the supercritical fluid extracts (Figure 3A). Ci_EtOAc showed
the most promising antibiofilm activity against C. albicans, slightly higher than the activity
of parthenolide. The antibiofilm activities of the chicory extracts were relatively high
compared to the antifungal agent ketoconazole, which achieved 73% inhibition at 0.5 MIC
(Figure 3A). Compounds 11β-13-dihydrolactucin, lactucopicrin, lactucin and costunolide
did not show antibiofilm activity at the tested subinhibitory concentrations, whereas the
activities of Ci_SFEpur and Ci_SFEopt were slightly higher but not significantly.
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Figure 2. Bioautographic assay of Ci_SFEopt and Ci_SFEpur developed in 85:15 (v/v) dichloromethane:methanol as the 
solvent. (A) Antibacterial activity against Staphylococcus aureus (oral isolate), S. aureus ATCC (left); and Pseudomonas aeru-
ginosa (right). (B) Antifungal activity against Candida albicans (left) and C. krusei (right). Spots on different Rf values: 1. Rf 
= 0.18 (activity only against S. aureus ATCC); 2. Rf = 0.20 (activity only against P. aeruginosa); 3. Rf = 0.65 (activity against 
S. aureus ATCC and C. albicans); 4. Rf = 0.71 (activity against all tested bacteria and fungi); 5. Rf = 0.76 (activity against all 
tested bacteria and fungi, except C. krusei); 6. Rf = 0.82 (activity against all tested microorganisms, except P. aeruginosa and 
C. krusei); 7. Rf = 0.88 (activity against all tested bacteria and fungi, except C. krusei). 
2.3. Antifungal Activity 
The development of antifungal drugs is challenging because both the pathogen and 
host are eukaryotic, limiting the number of suitable molecular targets. Drug-resistant fun-
gal strains have also been reported, including Candida species resistant to the common 
antifungal fluconazole [21]. We found that all our compounds and extracts inhibited the 
growth of the four Candida species we tested, as well as two strains of C. albicans (MIC = 
0.03–1.00 mg/mL) (Table 5A). The most potent extracts were Ci_SFEopt and Ci_SFEpur, 
which inhibited all five fungi in the test panel and achieved a MIC of 0.03 mg/mL against 
C. auris, which was lower than the MIC of any of the pure compounds. None of the tested 
Figure 2. Bioautographic assay of Ci_SFEopt and Ci_SFEpur developed in 85:15 (v/v) dichloromethane:methanol as the
solvent. (A) Antibacterial activity against Staphylococcus aureus (oral isolate), S. aureus ATCC (left); and Pseudomonas
aeruginosa (right). (B) Antifungal activity against Candida albicans (left) and C. krusei (right). Spots on different Rf values:
1. Rf = 0.18 (activity only against S. aureus ATCC); 2. Rf = 0.20 (activity only against P. aeruginosa); 3. Rf = 0.65 ( ctivity
against S. aureus ATCC and C. albicans); 4. Rf = 0.71 (activity against al teste bacteria and fungi); 5. Rf = 0.76 (activity
against all tested bacteria and fungi, except C. krusei); 6. Rf = 0.82 (activity against all tested microorganisms, except
P. aeruginosa and C. krusei); 7. Rf = 0.88 (activity against all tested bacteria and fungi, except C. krusei).
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Table 5. Antifungal activity of terpene extracts and pure compounds against (A) selected Candida species/strains and
(B) selected other fungal pathogens. MIC, minimal inhibitory concentration; MFC, minimal fungicidal concentration





ATCC 10231 C. krusei C. auris
C.
parapsilosis
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
Extracts
Ci_EtOAc 1.00 2.00 - - - - - - - -
Ci_H2O 1.00 2.00 - - - - - - - -
Ci_SFEpur 0.06 0.12 0.06 0.12 0.06 0.12 0.03 0.06 0.25 0.50
Ci_SFEopt 0.50 1.10 0.50 1.10 0.50 1.10 0.25 0.50 0.50 1.10
Standards
Costunolide 0.50 1.00 - - 0.13 0.25 - - - -
Parthenolide 0.25 0.50 - - 0.03 0.06 - - - -
Lactucin 1.00 >1.00 - - 0.50 1.00 - - - -
Lactucopicrin 1.00 >1.00 - - 0.50 1.00 - - - -
11β,
13-Dihydrolactucin 0.50 1.00 - - 0.50 1.00 0.25 0.50 0.25 0.50
Control
Ketoconazole 0.030 0.060 0.002 0.032 0.006 0.010 - - 0.003 0.006
(B)
A. fumigatus A. versicolor A. ochraceus A. niger T. viride P.ochrochloron
P.
funiculosum
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
Extracts
Ci_EtOAc - - 3.00 4.00 4.00 8.00 6.00 8.00 1.00 2.00 0.50 1.00 NA NA
Ci_H2O - - - - - - - - - - - - NA NA
Ci_SFEpur 0.13 0.26 0.03 0.06 0.25 0.50 0.50 1.00 NA NA NA NA 0.25 0.50
Ci_SFEopt 1.10 2.20 0.50 1.10 1.10 2.20 2.20 4.40 NA NA NA NA 1.10 2.20
Standards
Costunolide - - - - - - - - - - - - - -
Parthenolide - - - - - - - - - - - - - -
Lactucin - - - - - - - - - - - - - -
Lactucopicrin - - - - - - - - - - - - - -
11β,
13-Dihydrolactucin - - - - - - - - - - - - - -
Control
Ketoconazole 0.180 0.250 0.045 0.062 0.250 0.500 0.375 0.500 0.375 0.500 0.031 0.159 0.150 0.200
- No antifungal activity with the tested concentrations.
Given the promising antibacterial activity of the supercritical fluid extracts against
P. aeruginosa IBRS P001 (Table 3), the same extracts were also tested for their antibiofilm
activity against this bacterial pathogen. Remarkably, Ci_SFEpur achieved almost 60%
inhibition at 0.5 MIC (Figure 3B). Lactucopicrin and costunolide also reduced the formation
of P. aeruginosa IBRS P001 biofilms by ~50% at 0.5 MIC, whereas 11β-13-dihydrolactucin
showed no antibiofilm activity (Figure 3B). Based on the results of crystal violet assays and
the ability of CI_SFEopt and Ci_SFEpur to reduce P. aeruginosa biofilm biomass, we selected
these extracts for further antibiofilm assessment.
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Figure 3. Percentage inhibition of biofilm formation in (A) C. albicans 475/15 and (B) P. aeruginosa
IBRS P001 after treatment with chicory extracts and pure compounds. Results are presented as a
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MTT assays revealed that biofilm cell viability was significantly reduced (> 50%)
following Ci_SFEopt treatment, whereas Ci_SFEpur had a less profound effect (Figure 4A).
Biofilms are composed of microbial cells embedded in an extracellular matrix with ex-
opolysaccharides (EPS) and extracellular DNA (eDNA) as essential components; thus, we
investigated the effect of Ci_SFEopt and Ci_SFEpur on these factors. Ci_SFEopt (but not
Ci_SFEpur) was able to reduce the quantity of EPS in the biofilm (Figure 4B), whereas both
extracts reduced the quantity of eDNA (Figure 4C). Given that P. aeruginosa biofilms are
often present in catheter-associated infections, we determined whether the incubation of
catheters in MIC and sub-MIC amounts of Ci_SFEopt and Ci_SFEpur would reduce the
ability of P. aeruginosa to establish biofilms on the catheter surface. Both Ci_SFEopt and
Ci_SFEpur reduced the CFU count when applied at the MIC, with Ci_SFEopt showing the
stronger inhibitory potential (Figure 4D).
Pharmaceuticals 2021, 14, 941 10 of 20
Pharmaceuticals 2021, 14, 941 12 of 23 
 
 
showed no antibiofilm activity (Figure 3B). Based on the results of crystal violet assays 
and the ability of CI_SFEopt and Ci_SFEpur to reduce P. aeruginosa biofilm biomass, we se-
lected these extracts for further antibiofilm assessment. 
MTT assays revealed that biofilm cell viability was significantly reduced (> 50%) fol-
lowing Ci_SFEopt treatment, whereas Ci_SFEpur had a less profound effect (Figure 4A). Bio-
films are composed of microbial cells embedded in an extracellular matrix with exopoly-
saccharides (EPS) and extracellular DNA (eDNA) as essential components; thus, we in-
vestigated the effect of Ci_SFEopt and Ci_SFEpur on these factors. Ci_SFEopt (but not 
Ci_SFEpur) was able to reduce the quantity of EPS in the biofilm (Figure 4B), whereas both 
extracts reduced the quantity of eDNA (Figure 4C). Given that P. aeruginosa biofilms are 
often present in catheter-associated infections, we determined whether the incubation of 
catheters in MIC and sub-MIC amounts of Ci_SFEopt and Ci_SFEpur would reduce the abil-
ity of P. aeruginosa to establish biofilms on the catheter surface. Both Ci_SFEopt and 
Ci_SFEpur reduced the CFU count when applied at the MIC, with Ci_SFEopt showing the 
stronger inhibitory potential (Figure 4D). 
 
Figure 4. Modes of antibiofilm activity against P. aeruginosa IBRS P001 expressed as percentage inhibition compared to the 
untreated control. (A) Inhibition of biofilm cell viability determined by MTT assay. (B) Inhibition of biofilm exopolysac-
charide content. (C) Inhibition of biofilm eDNA. (D) Inhibition of biofilm CFU formed on urinary catheters. Results are 
expressed as mean (±stdev) of triplicates. 
The extracts Ci_SFEopt and Ci_SFEpur differ in the active compound spectra, which 
may result in the more profound antibiofilm effects in the cases of Figure 4A,B, i.e., puta-
tive synergistic action of higher number of active compounds may play a role, whereas in 
Figure 4. Modes of antibiofilm activity against P. aeruginosa IBRS P001 expressed as percentage inhibition compared
to the untreated control. (A) Inhibition of biofilm cell viability determined by MTT assay. (B) Inhibition of biofilm
exopolysaccharide content. (C) Inhibition of biofilm eDNA. (D) Inhibition of biofilm CFU formed on urinary catheters.
Results are expressed as mean (±stdev) of triplicates.
The extracts Ci_SFEopt and Ci_SFEpur differ in the active compound spectra, which
may result in the more profound antibiofilm effects in the cases of Figure 4A,B, i.e., putative
synergistic action of higher number of active compounds may play a role, whereas in
the case of biofilm eDNA (Figure 4C) inhibition by only purified fraction compounds are
sufficient to perform the action. Accordingly, antibiofilm activity is not strongly correlated
with eDNA. eDNA inhibition is one of the many mechanisms to reduce integrity of the
biofilm structure and is one of the causes of biofilm resistance to antimicrobials. It is not
surprising that both extracts exhibited the similar action on eDNA inhibition, although
Ci_SFEopt had more pronounced antibiofilm activity.
2.5. Inhibition of Pyocyanin Production by Pseudomonas aeruginosa IBRS P001
Pyocyanin is a Pseudomonas toxin that confers a competitive advantage by killing
other microbes, but it also kills mammalian cells. The inhibition of pyocyanin synthesis
helps to eradicate P. aeruginosa and can also prevent infection. The sesquiterpene lactones
were tested at 0.5 MIC for their ability to inhibit pyocyanin production by P. aeruginosa
(Table 6). Based on the concentration of pyocyanin (mg/mL) in treated bacterial cultures,
lactucin demonstrated the strongest effect (~70% inhibition) and 11β-13-dihydrolactucin the
weakest (~36% inhibition). The strong effect of these compounds on pyocyanin production
exists at sub-MIC levels.
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Table 6. Percentage inhibition of pyocyanin production in P. aeruginosa IBRS P001. The standard
compounds were applied at 0.5 MIC. The concentrations of pyocyanin in the treated cultures (mg/mL)
were compared to an untreated control to determine the percentage inhibition.
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15 min 30 min
Ci_EtOAc, in ethanol 1133 739 not harmful
Ci_EtOAc, in water 1891 1415 not harmful
Wit_EtOAc 203 184 not harmful
Wit_H2O 5737 6385 not harmful
Ci_SFE 83 68 harmful
Ci_SFEopt 131 142 not harmful
Ci_SFEpur 3076 c 1674 c not harmful
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We next assessed the antiproliferative effect of Ci_SFEopt and Ci_SFEpur in the im-
mortalized human keratinocyte line HaCaT, which is widely used as an in vitro model
for initial compound screening before progressing to skin irritation tests. Ci_SFEopt
showed weak cytotoxicity (IC50 = 303.42 µg/mL) whereas Ci_SFEpur was highly cyto-
toxic (IC50 = 16.76 µg/mL), suggesting that Ci_SFEopt is safe to use with caution whereas
Ci_SFEpur is potentially a potent skin irritant (Table 8). These results should be confirmed
in vivo. Potassium dichromate (K2Cr2O7) was used as positive control and showed the
strongest effect in the assay.
Table 8. Cytotoxicity of Ci_SFEopt and Ci_SFEpur toward HaCaT cells, presented as the
IC50 value (µg/mL). K2Cr2O7 was used as a positive control. Results are expressed as mean (±stdev)
of triplicates.
IC50 (µg/mL)
Ci_SFEopt 303.4 ± 1.5
Ci_SFEpur 16.8 ± 0.1
K2Cr2O7 0.9 ± 0.0
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We also tested the effect of witloof and chicory extracts in Caco-2 cells, which are
the preferred in vitro model of the intestinal epithelial barrier. In initial experiments, the
cells were exposed for 4 h (the commonly accepted period for gastrointestinal traffic) and
subsequently for 24 h, but the toxicity of the extracts was not enhanced by the longer
incubation. The witloof ethyl acetate extract (Wit_EtOAc) demonstrated cytotoxicity at
concentrations exceeding 2500 µg/mL (Figure 5A), whereas the aqueous extract (Wit_H2O)
showed no significant cytotoxicity until the concentration reached 5000 µg/mL (Figure 5B).
This is probably because water extracts the more polar compounds from witloof, including
sugars and inulin, which are not cytotoxic at the concentrations we tested. The Ci_EtOAc
was cytotoxic at concentrations > 1875 µg/mL, whereas Ci_SFEopt already showed cy-
totoxicity at 750 µg/mL (Figure 5C,D). The higher cytotoxicity of the supercritical fluid
extract reflected the higher selectivity of the SFE process for STL extraction, given that
the mass percentage of these compounds is higher in this extract compared to Ci_EtOAc.
Ci_SFEpur is highly enriched for 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin, and
this was more cytotoxic than Ci_SFEopt, affecting cell viability starting at a concentration of
375 µg/mL (Figure 5E). This higher toxicity is likely to be associated with the purification
of the most bioactive compounds from Ci_SFEopt, which overcomes the dilution effect
often observed in more complex mixtures.
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(B) Wit_H2O. (C) Ci_EtOAc. (D) Ci_SFEopt. (E) Ci_SFEpur. Results are presented as mean (±stdev) 
of three independent experiments. 
3. Discussion 
Natural compounds remain an important source of new drugs. During the period 
1981–2019, up to 67% of all approved small molecules were natural products or contained 
an active pharmacophore from a natural product [23]. Most current antibiotics are micro-
bial metabolites, but plant-derived compounds show promising activities and the number 
of scientific publications on this topic increases continually [24,25]. Among the 459 antibi-
otic compounds identified in plants, 50.8% are phenolic derivatives and 26.6% are terpe-
noids [26]. In our study, we detected several interesting bioactivities in extracts and puri-
fied compounds from chicory, an industrial crop that is not presently used for medicinal 
purposes. Importantly, the bioactive fraction can be obtained from an industrial waste 
stream. We prepared witloof and chicory extracts rich in STLs and tested them for differ-
ent bioactivities. Conventional solid–liquid extraction with water was generally less se-
lective for STLs than ethyl acetate, as reflected by the weaker bioactivity of the aqueous 
extracts. But SFE was more selective than ethyl acetate, achieving the highest overall STL 


















Figure 5. Cytotoxic profile of chicory extracts in Caco-2 cells after incubation for 4 h. (A) Wit_EtOAc.
(B) it_H2O. (C) Ci_EtOAc. (D) Ci_SFEopt. (E) Ci_SFEpur. Results are presented as mean (±stdev) of
three independent experiments.
Pharmaceuticals 2021, 14, 941 13 of 20
3. Discussion
Natural compounds remain an important source of new drugs. During the period
1981–2019, up to 67% of all approved small molecules were natural products or con-
tained an active pharmacophore from a natural product [23]. Most current antibiotics are
microbial metabolites, but plant-derived compounds show promising activities and the
number of scientific publications on this topic increases continually [24,25]. Among the
459 antibiotic compounds identified in plants, 50.8% are phenolic derivatives and 26.6%
are terpenoids [26]. In our study, we detected several interesting bioactivities in extracts
and purified compounds from chicory, an industrial crop that is not presently used for
medicinal purposes. Importantly, the bioactive fraction can be obtained from an industrial
waste stream. We prepared witloof and chicory extracts rich in STLs and tested them for
different bioactivities. Conventional solid–liquid extraction with water was generally less
selective for STLs than ethyl acetate, as reflected by the weaker bioactivity of the aqueous
extracts. But SFE was more selective than ethyl acetate, achieving the highest overall STL
yields. We found that the further optimization of SFE yielded chicory extracts with strong
antibacterial and antifungal activity, and others have likewise reported chicory extracts
with potent anti-inflammatory activity using a similar SFE method [11]. The mixture of
natural compounds found in plant extracts often demonstrates synergistic effects, as we
observed for our extracts. Whereas pure STLs demonstrated modest antifungal activity, the
chicory extracts containing mixtures of STLs showed strong antifungal effects. Remarkably,
the chicory supercritical fluid extract and a purified fraction consisting of 8-deoxylactucin
and 11β,13-dihydro-8-deoxylactucin inhibited the growth of both antibiotic-resistant bacte-
ria tested in this study (S. aureus MRSA and P. aeruginosa IBRS P001). Antibiotic resistance is
a major global health challenge that causes an immense burden on health care systems [13].
During the past 20 years, only two new antibiotic classes (lipopeptides and oxazolidinones)
have been approved that are suitable for the treatment of antibiotic-resistant bacteria,
and both target Gram-positive species [27]. Among the 44 intravenous antibiotics in the
clinical development pipeline, only 15 show activity against Gram-negative species such
as P. aeruginosa IBRS P001, and only five have progressed to phase III trials [28,29]. The
S. aureus MRSA strain used in this study is ranked as 13th on the WHO priority list of the
25 most severe pathogenic bacteria [29].
All current clinical antibiotics are either bactericidal or bacteriostatic, and growth
inhibition is achieved by interfering with essential cellular processes [30]. The resulting
selective pressure leads to the emergence of resistant strains, which rapidly spread in the
population. This can be addressed by focusing on the development of drugs that limit
selective pressure by targeting nonessential cellular processes, such as bacterial virulence,
quorum sensing, or the ability to form biofilms [26,31,32]. The formation of biofilms
during chronic infections is also one of several mechanisms used by pathogenic bacteria to
withstand antibiotics. We found that chicory extracts, especially those obtained by SFE,
were able to inhibit biofilm formation by P. aeruginosa IBRS P001. The extracts reduced
biofilm cell viability as well as the accumulation of EPS and eDNA in the extracellular
matrix. Further investigation revealed that chicory supercritical fluid extracts are promising
inhibitors of catheter-related biofilms.
The development of new antifungal agents safe for human use is challenging because
fungi and mammals are both eukaryotes and thus share many drug targets. The major
life-threatening fungal infections in humans are caused by species of Candida, Aspergillus
and Cryptococcus [33]. Only three types of antifungal drugs are currently available, and
this limited arsenal is threatened by the emergence of multidrug-resistant pathogens such
as C. auris, first reported in 2009 in Japan [34]. C. auris spreads rapidly in critically ill
patients to become a dominant opportunistic pathogen; thus, there is an urgent need for
new antifungal agents [35]. The strong antifungal activity of the chicory supercritical fluid
extract against C. auris is therefore an important step forward, particularly given the ability
of the purified extract to inhibit biofilm formation by C. albicans more effectively than
standard STLs.
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The therapeutic index of a drug is a measure of its relative safety and efficacy, with
a high score indicating the ideal situation in which a drug simultaneously shows high
activity against its target but low toxicity. In an initial acute toxicity screen, only the
crude supercritical fluid extract showed cytotoxicity, which declined when the SFE method
was optimized and with the fractionated extracts. A higher mass percentage of STL
compounds (as found in the supercritical fluid extracts) correlated with higher cytotoxicity
in HaCaT and Caco-2 cells, highlighting the dose-dependent bioactivity and toxicity of
these compounds.
Natural compounds offer a large and largely untapped resource of novel drug candi-
dates [36]. Our results demonstrate that chicory is a source of valuable bioactive compounds
with antimicrobial properties, and the isolation of chicory extracts and compounds from
industrial waste streams has the potential to create added value that can be exploited
to benefit human health. The same principles can be applied to many other underuti-
lized plants as well as plant-derived biomass generated as side streams or waste from
industrial processes.
4. Materials and Methods
4.1. Sample Extraction
We tested seven samples consisting of witloof or industrial chicory extracted with
different solvents. Freeze-dried witloof and fresh industrial chicory roots were extracted
with ethyl acetate (Wit_EtOAc, Ci_EtOAc) or water (Wit_H2O, Ci_H2O) at a raw material
to solvent ratio of 1:10 (w/v). Extraction was performed for 1 h at 60 ◦C, with constant
agitation at 900 rpm in an RW20.n mechanical stirrer (IKA, Staufen, Germany). Each extract
was passed through FILTER-LAB 125-mm qualitative filter paper (Scharlab, Barcelona,
Spain) before remaining particulates were removed by centrifugation in a model 5810 R
benchtop device (Eppendorf, Hamburg, Germany). The extracts were then dried in a rotary
evaporator under reduced pressure at 40 ◦C. SFE was applied to freeze-dried industrial
chicory (Ci_SFE) at a flow rate of 10 g/min CO2 with 10% ethanol as the co-solvent
(300 bar, 50 ◦C, 120 min). After SFE process optimization for freeze-dried industrial chicory
(Ci_SFEopt), extracts were prepared at a flow rate of 15 g/min CO2 with 10% ethanol as
the co-solvent (350 bar, 40 ◦C, 120 min). The Ci_SFEopt extract and Ci_SFEpur (purified
fraction) were prepared as previously described [11].
4.2. Identification of STLs
STLs were identified by HPLC on a Dionex Ultimate 3000 device equipped with a qua-
ternary pump, solvent degasser, autosampler, and column oven, coupled to a Dionex DAD-
3000 photodiode array detector (all from Thermo Fisher Scientific, Waltham, MA, USA).
Samples were fractionated on a LiCrospher 100 RP-18, 250 mm × 4 mm (5 µm) reversed-
phase column (Merck, Darmstadt, Germany) at 35 ◦C, and were eluted in a gradient of mo-
bile phase A (14:86 (v/v) methanol/water) and mobile phase B (64:36 (v/v) methanol/water).
The gradient program was 0 to 20 min, 100–58% A; 20 to 30 min, 58% A; 30 to 45 min,
58–0% A; 45 to 50 min, 0% A; 50 to 52 min, 0–100% A; 52 to 62 min, 100% A. The flow
rate was 0.5 mL/min, and the injection volume was 20 µL. A photodiode array detector
was used to scan for absorption in the range 210–600 nm. Data were analyzed using
Chromeleon v7.2 SR4. Ethanol was the preferred solvent for sample preparation.
4.3. Antimicrobial Activity
Antimicrobial activity in cultures spiked with terpene compounds and extracts was
tested as previously described [37] with modifications [38], or using an automated Bio-
screen turbidimeter (Labsystems, Helsinki, Finland) [39]. Pure standard compounds
(lactucopicrin, 11β-13-dihydrolactucopicrin, lactucin and parthenolide) and extracts were
tested against S. aureus VTT E-70045 (ATCC 6538), P. aeruginosa VTT E-96728 (ATCC 9027)
and E. coli VTT E-94564T (ATCC 11775) in Mueller-Hinton broth (Sigma-Aldrich, St Louis,
MO, USA). Stock solutions of the standard compounds (4 mM) were prepared in DMSO.
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Microbial growth was monitored in duplicate at 37 ◦C for 48 h. Each sample was analyzed
as duplicates.
The antimicrobial activity of the samples was also tested by analyzing the type of
growth inhibition (biostatic or biocidal) using a modified microdilution method [40] and
bioautography on TLC plates [41]. We tested S. aureus (oral isolate), S. aureus ATCC 11632,
P. aeruginosa ATCC 27853, P. aeruginosa IBRS P001, and E. coli 25922. We also tested Ci_SFEopt
and Ci_SFEpur against Proteus mirabilis ATCC 7002, Listeria monocytogenes NCTC 7973,
Yersinia enterocolitica ATCC 23715, Klebsiella pneumoniae ATCC 13883, Campylobacter jejuni
ATCC 33560, and Enterobacter cloacae human isolate. Briefly, bacterial suspensions were ad-
justed with sterile saline to a concentration of 1.0 × 105 CFU/mL. Extracts and compounds
dissolved in 30% ethanol were added in 100 µL tryptic soy broth (TSB) to a bacterial inocu-
lum of 1.0 × 104 CFU per well. The highest test concentration was 8 mg/mL for the extracts
and 1 mg/mL for the compounds. The lowest concentrations that completely inhibited
bacterial growth (MICs) were determined visually under a binocular microscope and also
by a colorimetric microbial viability assay based on the reduction of p-iodonitrotetrazolium
violet (Sigma-Aldrich) compared to positive control compounds for each bacterial strain.
MBCs were determined by the serial dilution of 2 µL culture samples into microtiter plates
containing 100 µL of fresh medium per well, followed by incubation for 24 h. The lowest
concentration with no visible growth was defined as the MBC, indicating the death of 99.5%
of cells from the original inoculum. Ampicillin and streptomycin were used as positive
controls, and the solvent ethanol as a negative control. All tested species are available at the
Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research
“Siniša Stankovic”, University of Belgrade.
In the modified bioautographic method [41], we applied 10 µL of Ci_SFEopt and
Ci_SFEpur (2 mg/mL in 30% ethanol) to a Kieselgel 60 F254 TLC plate (Merck) and fraction-
ated the duplicate samples using an 85:15 (v/v) mixture of dichloromethane and methanol
as the mobile phase. The position of the first tape was 1.50 cm from the left and 1.00 cm
from the bottom. The distance between the tapes was 1.30 cm. The development time of the
panel was 18 min, and the separation path was 8.5 cm in length. The absorbent layers were
dried in an oven at 90 ◦C for 5 min to remove the solvent. One of the strips was visualized
under UV light and the second strip was used for the bioautography assay. The Rf value of
each spot was measured. The dried plates were sprayed with freshly prepared cultures
(1.0 × 105 CFU/mL in TSB) of S. aureus (oral isolate), S. aureus (ATCC 11632), P. aeruginosa
(ATCC 27853), C. albicans (oral isolate) and C. krusei (oral isolate). The plates were incubated
in a water–vapor chamber for 24 h at 37 ◦C before spraying with 3% p-iodonitrotetrazolium
violet. After storage for 3 h, the plates were sprayed with 70% ethanol to stop bacterial
and fungal growth. Microbial growth inhibition appeared as clear zones against a pink
background and the Rf values of the spots showing inhibition were determined.
4.4. Antifungal Activity
We determined the MIC and minimal fungicidal concentrations (MFC) of the com-
pounds against A. fumigatus ATCC 9197, A. niger ATCC 6275, A. versicolor ATCC 11730,
P. funiculosum ATCC 36839, C. albicans 475/15 (clinical isolate), C. albicans ATCC 10231,
C. krusei H1/16 (clinical isolate), C. auris ATCC B 11903 and C. parapsilosis ATCC 22109 by
applying the microdilution technique in 96-well microtiter plates [42] with modifications.
As above, the highest test concentration was 8 mg/mL for extracts and 1 mg/mL for pure
compounds. Briefly, fungal cultures were diluted in sterile saline to ~1.0 × 105 CFU/per
well. MIC and MFC values were determined by incubating fungal cells in Sabouraud
dextrose broth (SDB, Merck) with serial dilutions of compounds at 37 ◦C for 24 h (yeast)
and at 25 ◦C for 72 h (filamentous fungi). The MIC was the lowest concentration of each
compound at which no visible fungal growth was observed by microscopy. After serial
sub-cultivation by transferring 10 µL of each culture to microtiter plates containing 100 µL
SDB/well, followed by incubation as above, MFC values were the lowest concentrations
at which no visible fungal growth was observed by microscopy, indicating the death of
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99.5% of the original inoculum. Fungal isolates were maintained on Sabouraud dextrose
agar (Merck) at 4 ◦C and were subcultured monthly. Ketoconazole (Sigma-Aldrich) was
used as a positive control and the solvent ethanol as a negative control.
4.5. Antibiofilm Activity
4.5.1. Calculation of Percentage Inhibition
Antibiofilm assays were conducted as previously described [43], with modifications,
using C. albicans 475/15 growing in yeast extract–peptone–dextrose (YPD) medium (Merck)
and P. aeruginosa IBRS P001 [44] growing in TSB + 2% glucose (Torlak Institute of Im-
munology and Virology, Belgrade, Serbia). C. albicans and P. aeruginosa were incubated in
96-well microtiter plates with adhesive bases (Sarstedt, Nümbrecht, Germany) at 37 ◦C
with sub-MIC concentrations of each compound. After 24 h, each well was washed twice
with sterile phosphate buffered saline (PBS, pH 7.4) and the adherent cells were fixed in
methanol. The plates were then air dried and the cells were stained with 0.1% crystal
violet (bioMerieux, Marcy-l’Étoile, France) for 30 min. The wells were washed with PBS to
remove excess stain and air dried before adding 100 µL 96% ethanol (Zorka Pharma, Šabac,
Serbia) to solubilize the stain. Absorbance at 620 nm was measured on a Multiskan FC
microplate photometer (Thermo Fisher Scientific) and the percentage inhibition of biofilm
formation was calculated using the following equation:
%Inhibition = [(A620control − A620sample)/A620control] × 100.
4.5.2. Biofilm Cell Viability MTT Assay
The effect of Ci_SFEopt and Ci_SFEpur on P. aeruginosa IBRS P001 biofilm formation
was determined by assessing the metabolic activity of live cells using an MTT assay [45].
Biofilms were allowed to develop for 24 h at 37 ◦C in the presence of Ci_SFEopt and
Ci_SFEpur (0.25–1.0 MIC). The supernatants were then removed and the biofilms in the
microtiter plates were washed with PBS before adding 200 µL MTT reagent (0.5 mg/mL)
and incubating at 37 ◦C in the dark for 2 h. The resulting purple dye was dissolved in
200 µL DMSO and the absorbance was measured at 570 nm in a microtiter plate reader. The
percentage inhibition of biofilm cell viability was calculated using the following equation:
%Inhibition = [(A570control − A570sample)/A570control] × 100.
4.5.3. Congo Red EPS-Binding Assay
EPS production by P. aeruginosa IBRS P001 biofilm was measured as previously de-
scribed 44, with modifications. Biofilms were formed in the presence of Ci_SFEopt and
Ci_SFEpur (0.25–1 MIC) for 24 h at 37 ◦C. The planktonic cells were then discarded, and
the adherent cells were washed with PBS and stained with 1% (w/v) Congo red in the
dark for 30 min. Excess dye was removed and the bound dye was solubilized with 200 µL
DMSO. Absorbance at 490 nm was measured in a microtiter plate reader and the percentage
inhibition of EPS production was calculated using the following equation:
%Inhibition = [(A490control − A490sample)/A490control] × 100
4.5.4. Quantification of eDNA
The quantity of eDNA was determined as previously described [46], with modifica-
tions. P. aeruginosa was grown in 96-well plates containing 200 µL TSB + 2% glucose per
well, with and without Ci_SFEopt or Ci_SFEpur (0.25–1.0 MIC). After incubation at 37 ◦C
for 24 h, the planktonic cells were removed, and the wells were washed with PBS. We then
added 150 µL TE buffer to the wells and mixed vigorously by pipetting. The solution was
transferred to 1.5-mL tubes and centrifuged at 10,000× g for 10 min. The supernatant was
removed, and the pellet resuspended in 100 µL TE buffer by vortexing before centrifugation
at 10,000× g for 15 min. The amount of eDNA was quantified by measuring the absorbance
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at 260 nm, with Milli-Q water as the blank. We calculated percentage depletion of eDNA
relative to an untreated control.
4.5.5. Catheter Model of Biofilm Formation
Sterile silicon 16-mm Romed catheters (Van Oostveen Medical, Wilnis, The Nether-
lands) were cut into 1 cm lengths and placed in 24-well plates. We then added P. aeruginosa
IBRS P001 in TSB + 2% glucose and the test compounds (0.25–1.0 MIC). After incubation at
37 ◦C for 24 h, the catheters were washed with PBS and transferred to 1.5 mL Eppendorf
tubes before adding 1 mL PBS and vortexing vigorously. The samples were diluted, seeded
onto plate-count agar (HiMedia Laboratories, Mumbai, India) and incubated at 37 ◦C for
24 h. We then determined the CFU count and determined the percentage inhibition relative
to the untreated control.
4.6. Inhibition of Pseudomonas aeruginosa IBRS P001 Pyocyanin Production
Overnight cultures of P. aeruginosa (109 CFU) in 1 mL lysogeny broth (LB) were
incubated at 37 ◦C for 48 h in the presence of each compound (0.5 MIC). The treated culture
was centrifuged, and the supernatant was extracted with chloroform and mixed with
0.2 M HCl. We measured the absorbance of the organic layer at 520 nm using a UV1601
spectrophotometer (Shimadzu, Kyoto, Japan). The inhibition of pyocyanin production
compared to untreated controls was calculated using the following equation:
%Inhibition = [(A520control − A520sample)/A520control] × 100.
The standard pyocyanin compound was serially diluted and the absorbance was
measured as described above. Concentrations of pyocyanin in the control and treated
cultures were presented in mg/mL using a calibration curve for standard compounds.
4.7. Toxicity
4.7.1. Photobacterial Acute Toxicity Assay
Acute toxicity tests followed the ISO 21338 standard method adapted to the 96-well
plate format. We used the BioTox kit (Aboatox, Turku, Finland) with freeze-dried A. fischeri
according to the supplier’s instructions, with minor modifications. Before each test, the
freeze-dried bacteria were rehydrated and stabilized at 4 ◦C for 1 h, followed by 1 h at
10 ◦C and final stabilization at 20 ◦C for 10 min. We used 96-well flat-bottom polystyrene
microtiter plates at ambient temperature (20–21 ◦C). Bioluminescence was measured in a
Fluoroscan Ascent FL microplate automated luminometer (ThermoLabsystems, Helsinki,
Finland) equipped with an automatic dispenser and mixer. Sample stocks were prepared
in DMSO, unless otherwise stated. We pipetted 140 µL of sample into each well, followed
by the automatic addition of 140 µL bacterial suspension. Luminescence was recorded
continuously for 6 s, the maximum was noted, and the results were normalized to the
peak value. The measurements were repeated after 15 and 30 min. Toxicity was expressed
as the effective concentration causing 50% bioluminescence inhibition (EC50) as recom-
mended by ISO 21338. Unless otherwise stated, duplicate toxicity assays were prepared for
eight serial two-fold dilutions of each sample. Each run included 3,5-dichlorophenol as a
positive control.
4.7.2. HaCaT Cell Antiproliferative Activity Assay
The antiproliferative effect of Ci_SFEopt and Ci_SFEpur was determined in HaCaT
cells grown in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1% penicillin and streptomycin
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) at 37 ◦C in a 5% CO2 atmosphere.
We seeded 1 × 104 cells/well in a 96-well plate 24 h before treatment. The medium was
removed and replaced with fresh medium supplemented with different concentrations of
the extracts and test compounds (6.25–400 µg/mL in PBS). Potassium dichromate (K2Cr2O7)
was used as a positive control and PBS as a negative control. Cells were incubated with
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each test material in triplicate for 24 h. The medium was then removed, and the cells
were washed twice with PBS and stained with 0.5% crystal violet for 15 min at room
temperature. The stain was removed, and the cells were washed in tap water before air-
drying at room temperature for 24 h. The dye was then dissolved in methanol and the
absorbance at 590 nm was measured in a microplate reader. The results were expressed as
IC50 values (µg/mL). The cytotoxic activity of the extracts was categorized as follows: m,
IC50 21–200 µg/mL = moderately cytotoxic, IC50 201–400 µg/mL = weakly cytotoxic, and
IC50 > 401 µg/mL = no cytotoxicity.
4.7.3. Caco-2 Cell Cytotoxicity Assay
Cytotoxic activity against Caco-2 cells were evaluated using the PrestoBlue cell vi-
ability assay (Thermo Fisher Scientific) as previously described [47]. Confluent Caco-2
cells were exposed to different concentrations of extracts or test compounds in culture
medium at 37 ◦C in a 5% CO2 atmosphere for 4 or 24 h. Cells were then incubated with
5% (v/v) PrestoBlue in culture medium as above for 2 h. Fluorescence was measured in
an FLx800 fluorescence microplate reader (BioTek Instruments, Winooski, VT, USA) at
excitation/emission wavelengths of 560/590 nm. Cell viability was determined relative to
an untreated control, after blank correction.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14090941/s1, Figure S1: Chromatograms of the commercially available sesquiterpene lactones
standards present in Cichorium intybus L. analyzed by HPLC-UV at 280 nm: 11β,13-dihydrolactucin
(RT = 23.7 min); Lactucin (RT = 27.3 min); 11β,13-dihydrolactucopicrin (RT = 48.6 min) and lactucopi-
crin (RT = 49.1 min). Figure S2: Antimicrobial activity of 1 mg/mL Wit_EtOAc, Wit_H2O and Ci_SFE
against Staphylococcus aureus VTT E-70045 in liquid cultures incubated for 48 h. Black diamond,
microbial control; gray triangle, Wit_EtOAc; black cross, Wit_H2O; gray square, Ci_SFE; gray circle,
chloramphenicol 50 µg/mL.
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Efficient Fungicide against Aspergillus Rot on Cherry Tomato and Cytotoxic Agent on Human Cell Lines. Ann. Appl. Biol. 2019,
175, 228–235. [CrossRef]
19. Madigan, M.T.; Martinko, J.M.; Parker, J. Brock Biology of Micro-Organisms; Carlson, G., Ed.; Pearson Education Ltd.: London, UK,
2006.
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